Biosimilar Resource Center

Infliximab Biosimilar Shown Noninferior for Chron’s Disease

A new study looking at CTP-13, a biosimilar to infliximab ( Remicade ), showed that the biosimilar was noninferior to the innovator product. The biosimilar CT-P13, based on the reference product infliximab, was originally approved...

BIOSIMILARS NEWS

Study: Rituximab Originator and Biosimilar Equivalent in iTTP Patients

A recent study published in the British Journal of Haematology looked at immune thrombotic thrombocytopenic purpura (iTTP), an acute multisystem thrombotic microangiopathy mediated by...
FDA Approves First Nr-axSpA Drug

The Current Status and Future Perspectives on Biosimilars in India

The outlook for the use and integration of biosimilars into the Indian market holds promise for reducing treatment costs and improving accessibility, a newly...

The Nocebo Effect in Biosimilar-treated Patients with Irritable Bowel Syndrome

A new consensus document of recommendations for the prevention of the “nocebo” effect in biosimilar-treated patients with irritable bowel disease (IBD) noted that the...

Biosimilars: Considerations for Payers

Cost and savings will ultimately play a key role in determining the acceptance of biosimilars, and in coming years, biosimilars are expected to increase...

Biosimilarity Assessment of Biosimilar Therapeutic Monoclonal Antibodies

As biosimilars continue to integrate into pharmacologic arsenals around the world, they are expected to abate medical expenses, allowing patients to access the drug...

Biosimilars in IBD: Similarity Breeds Content Patients

In the last two decades, patients with inflammatory bowel disease (IBD) have reaped the benefits of the advancements made in biologic therapy, which has...

Update and Current Challenges for Biosimilars in Japan

Despite its benefits, biosimilars are currently underutilized in Japan, where a lack of information and educational activities have created an environment non-conducive for full...
click me